04/11/2026
Topical retinoids are among the most extensively studied molecules in dermatology and remain a cornerstone of evidence-based therapy for acne, photoaging, and pigmentary disorders. Retinol is converted in the skin to retinoic acid, the biologically active form that binds nuclear receptors (RAR/RXR) and regulates gene expression involved in epidermal turnover, differentiation, and dermal remodeling.
Stratum corneum (surface layer)
Retinoids normalize keratinocyte differentiation
and accelerate epidermal turnover, producing a
more compact and uniform stratum corneum.
This improved organization can create the
impression of “thinner” skin, although the
change primarily reflects barrier normalization.
Viable epidermis
Histologic studies demonstrate that retinoids stimulate keratinocyte proliferation, resulting in epidermal thickening, elongation of dermal papillae, and improved structural integrity of the epidermal barrier.
Dermis
Retinoids activate fibroblasts and increase
synthesis of type I and Ill collagen, while
reducing collagen degradation mediated by
matrix metalloproteinases (MMPs). These
changes contribute to improved dermal matrix
organization and structural support.
Clinical interpretation
Retinoids do not simply “thin” or “thicken” skin.
Instead, they reorganize skin architecture across multiple layers: compacting the stratum corneum, thickening the living epidermis, and supporting dermal collagen remodeling.
Treatment outcomes depend on factors such as formulation, concentration, barrier condition, and
application frequency, which is why gradual introduction and barrier-supportive skincare are essential for optimal tolerance and results.
